Clever Leaves (NASDAQ:CLVR) & Synaptogenix (NASDAQ:SNPX) Head to Head Review

Clever Leaves (NASDAQ:CLVR) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Insider & Institutional Ownership

6.9% of Clever Leaves shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by insiders. Comparatively, 4.3% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Clever Leaves and Synaptogenix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clever Leaves	N/A	N/A	N/A
Synaptogenix	N/A	-7.45%	-5.65%

Valuation & Earnings

This table compares Clever Leaves and Synaptogenix”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clever Leaves	$17.42 million	0.10	-$17.90 million	($11.31)	-0.09
Synaptogenix	N/A	N/A	-$6.04 million	N/A	N/A

Synaptogenix has lower revenue, but higher earnings than Clever Leaves.

Volatility & Risk

Clever Leaves has a beta of 2, meaning that its share price is 100% more volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Clever Leaves and Synaptogenix, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clever Leaves	0	0	0	0	N/A
Synaptogenix	0	0	1	0	3.00

Synaptogenix has a consensus target price of $14.00, indicating a potential upside of 333.44%. Given Synaptogenix’s higher possible upside, analysts clearly believe Synaptogenix is more favorable than Clever Leaves.

Summary

Clever Leaves beats Synaptogenix on 5 of the 9 factors compared between the two stocks.

About Clever Leaves

Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.

About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.